Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing partnership with Samsung Biologics (KRX: 207940) for the production of an unnamed oncology antibody drug. This new agreement signifies a further step in the collaboration between the two companies, focusing on enhancing the manufacturing capabilities for BMS’s oncology pipeline.
Samsung Biologics to Manufacture at Largest Facility in Korea
Under the terms of the expanded agreement, Samsung Biologics will be responsible for producing the antibody drug at its largest biomanufacturing facility located in South Korea. This strategic move is expected to bolster the production capacity and efficiency for the unnamed drug, which is aimed at treating various types of cancer.
Strengthening the Oncology Portfolio
The collaboration with Samsung Biologics is a significant development in Bristol Myers Squibb’s ongoing efforts to strengthen its oncology portfolio. By leveraging Samsung Biologics’ state-of-the-art manufacturing capabilities, BMS is poised to enhance the global supply of its life-saving oncology therapies.-Fineline Info & Tech
